Spatially informed comprehensive tumor transcriptomic profiling stratifies clinical outcomes in early triple negative breast cancer

09 Jul 20264 min read0 viewsVerified Feed

GIST (Key Takeaways)

The intensification of neoadjuvant therapy for early triple-negative breast cancer (eTNBC) - through the addition of carboplatin to standard chemotherapy and the incorporation of pembrolizumab - has markedly improved prognosis in recent years. However, this escalation carries a substantial risk of toxicity, and not all patients require the full regimen to achieve benefit.
Realizing individualized treatment strategies will therefore depend on prognostic and predictive biomarkers that can forecast treatment response and long-term outcome. In the present study, we interrogated public gene expression datasets to develop transcriptomic signatures predicting response to neoadjuvant treatment and risk of recurrence.
To validate these signatures, we used the Multiplex8+ platform for spatially informed comprehensive transcriptomic profiling in a real-world, multicenter, retrospective cohort of 590 patients diagnosed with eTNBC and treated with neoadjuvant chemotherapy with or without immunotherapy. The diagnostic Multiplex8+ test uses H&E and multiplexed RNA-FISH to guide the selection of specific tumor areas for the whole transcriptome sequencing and signature analysis.

Clinical Editorial

medRxiv (Clinical Preprints) published a clinical update in Research Highlights on 09 Jul 2026.

The item focuses on Spatially informed comprehensive tumor transcriptomic profiling stratifies clinical outcomes in early triple negative breast cancer.

Review the original article for the full source wording and details.